Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Pieri

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
American Journal of Hematology|May 7, 2019
Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosisFrancesco Mannelli, Francesca Gesullo, Giada Rotunno, et al.
American Journal of Hematology|February 17, 2015
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosisTiziano Barbui, Alessandro M Vannucchi, Alessandra Carobbio, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 18, 2009
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasmsAlessandro M Vannucchi, Giovanna Masala, Elisabetta Antonioli, et al.
Blood|June 25, 2009
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allelePaola Guglielmelli, Giovanni Barosi, Giorgina Specchia, et al.
American Journal of Hematology|September 3, 2013
Masked polycythemia vera (mPV): results of an international studyTiziano Barbui, Jürgen Thiele, Heinz Gisslinger, et al.
Blood|January 21, 2014
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohortsFrancesco Passamonti, Margherita Maffioli, Francisco Cervantes, et al.
Cancer|November 22, 2013
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyureaSrdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, et al.
Blood|January 25, 2014
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II studyPaola Guglielmelli, Flavia Biamonte, Giada Rotunno, et al.
Blood|May 3, 2011
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progressionThorsten Klampfl, Ashot Harutyunyan, Tiina Berg, et al.
British Journal of Haematology|August 19, 2014
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia veraFederico Lussana, Alessandra Carobbio, Maria L Randi, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
American Journal of Hematology|May 7, 2019
Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosisFrancesco Mannelli, Francesca Gesullo, Giada Rotunno, et al.
American Journal of Hematology|February 17, 2015
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosisTiziano Barbui, Alessandro M Vannucchi, Alessandra Carobbio, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 18, 2009
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasmsAlessandro M Vannucchi, Giovanna Masala, Elisabetta Antonioli, et al.
Blood|June 25, 2009
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allelePaola Guglielmelli, Giovanni Barosi, Giorgina Specchia, et al.
American Journal of Hematology|September 3, 2013
Masked polycythemia vera (mPV): results of an international studyTiziano Barbui, Jürgen Thiele, Heinz Gisslinger, et al.
Blood|January 21, 2014
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohortsFrancesco Passamonti, Margherita Maffioli, Francisco Cervantes, et al.
Cancer|November 22, 2013
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyureaSrdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, et al.
Blood|January 25, 2014
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II studyPaola Guglielmelli, Flavia Biamonte, Giada Rotunno, et al.
Blood|May 3, 2011
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progressionThorsten Klampfl, Ashot Harutyunyan, Tiina Berg, et al.
British Journal of Haematology|August 19, 2014
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia veraFederico Lussana, Alessandra Carobbio, Maria L Randi, et al.
Pageof 6